Refractory hyperammonemic encephalopathy in Fibrolamellar hepatocellular carcinoma: a case report and literature review

Fibrolamellar hepatocellular carcinoma is a rare type of hepatocellular carcinoma with unclear etiology. Its prevalence ranges from 0.6%-5%. One of the rare manifestations of FHCC includes hyperammonemic hepatic encephalopathy (HAE). Data regarding HAE in FHCC is limited to case reports, and much is...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Ahmed, Arwa (VerfasserIn) , Ata, Fateen (VerfasserIn) , Gaber, Mohammed (VerfasserIn) , Petkar, Mahir (VerfasserIn) , Mahfouz, Ahmed (VerfasserIn) , Schirmacher, Peter (VerfasserIn) , Musa, Sara (VerfasserIn) , Hashim, Ahmed (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2 March 2022
In: Current problems in cancer
Year: 2022, Jahrgang: 46, Heft: 3, Pages: 1-9
ISSN:1535-6345
DOI:10.1016/j.currproblcancer.2022.100847
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.currproblcancer.2022.100847
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S014702722200006X
Volltext
Verfasserangaben:Arwa Ahmed, Fateen Ata, Mohammed Gaber, Mahir Petkar, Ahmed Mahfouz, Peter Schirmacher, Sara Musa, Ahmed Hashim
Beschreibung
Zusammenfassung:Fibrolamellar hepatocellular carcinoma is a rare type of hepatocellular carcinoma with unclear etiology. Its prevalence ranges from 0.6%-5%. One of the rare manifestations of FHCC includes hyperammonemic hepatic encephalopathy (HAE). Data regarding HAE in FHCC is limited to case reports, and much is unknown, including its precipitating factors, clinical course, and management. We have reported one such case of FHCC associated HAE and presented an extensive literature review on the topic. We report the case of a 26-year-old Pakistani male who was diagnosed with fibrolamellar hepatocellular carcinoma. ...
Beschreibung:Artikel-Version vom 8. März 2022
Gesehen am 14.11.2023
Beschreibung:Online Resource
ISSN:1535-6345
DOI:10.1016/j.currproblcancer.2022.100847